Fosun Pharma (02196) subsidiary Fosun Pharma Industry signed a "License Agreement" with NewCo.

Zhitan Finance and Economics APP News, Fosun Pharma (02196) announced on July 28, 2025 that its controlling subsidiary, Fosun Pharma Industry, signed a "License Agreement" with Neurocode. According to the agreement, Fosun Pharma Industry was granted by Neurocode the rights to develop, register, produce, and commercialize drugs using the AR1001 molecule as its active ingredient in the agreed license area (namely, Mainland China, Hong Kong, Macau) and field (namely, for the diagnosis, prevention, and treatment of Alzheimer's disease and other neurological disorders).